SS
ALDR

Steve Schonfeld’s Alder Biopharmaceuticals ALDR Stock Holding History

Steve Schonfeld’s Portfolio ALDR Stock Details ALDR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-52,800
Closed -$622K – 1356
2019
Q2 		$622K Sell
52,800
-200,400
-79% -$2.43M 0.02% 575
2019
Q1 		$3.46M Sell
253,200
-118,500
-32% -$1.54M 0.12% 228
2018
Q4 		$3.81M Buy
371,700
+18,000
+5% +$230K 0.15% 195
2018
Q3 		$5.89M Buy
353,700
+276,700
+359% +$5M 0.26% 108
2018
Q2 		$1.22M Sell
77,000
-104,234
-58% -$1.58M 0.07% 361
2018
Q1 		$2.3M Buy
+181,234
New +$2.62M 0.17% 170
2017
Q3 		– Sell
-53,865
Closed -$617K – 851
2017
Q2 		$617K Sell
53,865
-21,135
-28% -$391K 0.06% 358
2017
Q1 		$1.56M Buy
+75,000
New +$1.66M 0.16% 182
2016
Q4 		– Sell
-9,321
Closed -$305K – 691
2016
Q3 		$305K Buy
9,321
+106
+1% +$3.23K 0.05% 314
2016
Q2 		$230K Buy
+9,215
New +$249K 0.05% 358

Other funds holding ALDR

RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
CC
Carlson Capital Dallas, Texas $494M AUM 23.45% 1-Year Est. Return
DKCM
Davidson Kempner Capital Management New York $8.42B AUM 61.81% 1-Year Est. Return
AAM
Alpine Associates Management Palm Beach, Florida $1.6B AUM 93.19% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $16.4B AUM 55.44% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Steve Schonfeld's ALDR Position: Q3 2019 in Review

Steve Schonfeld sold out of Alder Biopharmaceuticals (ALDR) in Q3 2019, closing a stake of 52,800 shares — an estimated $622K sold.

Steve Schonfeld first reported a position in ALDR in Q2 2016 and held it in 10 quarters. The position peaked at $5.89M in Q3 2018. 143 funds tracked by Wall St. Rank hold ALDR as of Q3 2019.

  • Steve Schonfeld reported no remaining Alder Biopharmaceuticals position as of Q3 2019 after selling out during the quarter.
  • Steve Schonfeld sold 52,800 Alder Biopharmaceuticals shares in Q3 2019, an estimated $622K.
  • Steve Schonfeld first reported a position in Alder Biopharmaceuticals in Q2 2016 and held it in 10 quarters.
  • Steve Schonfeld's Alder Biopharmaceuticals position peaked at $5.89M in Q3 2018.
  • 143 funds tracked by Wall St. Rank held Alder Biopharmaceuticals as of Q3 2019.

Based on Schonfeld Strategic Advisors's 13F filing for Q3 2019, filed 14 Nov 2019.